{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"SMARCA4, a tumor suppressor involved in chromatin remodeling, is recurrently altered in small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT).",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"12/20/2017",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "24658002",
        "24658001",
        "24658004",
        "25060813",
        "18301784"
      ]
    },
    "description":"The majority of SMARCA4 mutations are nonsense, frameshift or splice-site mutations, leading to truncation or total loss of the SMARCA4 protein (PMID: 24658002, 24658004, 24658001, 25060813). The ATPase domain and bromodomain of SMARCA4 are located in the C-terminal part of the protein, which are particularly affected by truncating mutations, rendering SMARCA4 enzymatically-dead and non-functional (PMID: 18301784). The bromodomain is thought to be critical for SMARCA4 binding to acetylated histones and guiding the SWI/SNF complex to the chromatin (PMID: 18301784).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"E1144*",
    "alterationType":null,
    "consequence":null,
    "entrezGeneId":6597,
    "hgvs":null,
    "hugoSymbol":"SMARCA4",
    "id":null,
    "proteinEnd":null,
    "proteinStart":null,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The SMARCA4 E1144* mutation is likely oncogenic.",
  "vus":false
}